Study of targeted therapy plus immunotherapy for HER2-low stomach cancer
Part of Cancer, Digestive system clinical trials.
This trial is testing a new combination of drugs (targeted therapy plus immunotherapy plus chemotherapy) for people with a specific type of advanced stomach cancer called HER2-low. The goal is to see if this combination works better than the current standard immunotherapy plus chemotherapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your stomach cancer must be advanced (cannot be removed by surgery) or has spread to other parts of the body.
- You must not have received any treatment for your advanced stomach cancer yet.
- Your tumor must be HER2-low (a specific lab test result).
- You must be able to take care of yourself (fully active or able to do light work).
- You must not have any other serious health problems like lung disease, uncontrolled diarrhea, or cancer that has spread to the brain.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of drugs (Disitamab Vedotin, Trastuzumab, and Tislelizumab) against standard chemotherapy plus Trastuzumab (with or without Pembrolizumab) for people with advanced or metastatic stomach or gastroesophageal junction cancer that has high levels of HER2. The goal is to see if the new combination works better.
This trial tests a combination of three drugs (targeted therapy, immunotherapy, and chemotherapy) before and after surgery for locally advanced HER2-positive stomach cancer. It aims to see if this treatment can improve outcomes for patients whose cancer has not yet spread.
This trial tests a combination of three drugs (Disitamab Vedotin, Toripalimab, and XELOX) given before and after surgery for gastric or gastroesophageal junction cancer. The goal is to see if this treatment helps shrink the tumor and prevent it from coming back.
This trial tests a new combination of drugs (RC48, sintilimab, and SOX chemotherapy) for people with stomach or gastroesophageal junction cancer that cannot be removed by surgery, has not been treated before, and has a specific HER2 score (1+ or 2+). The goal is to shrink the tumor enough to possibly allow surgical removal.
This trial tests a new approach for stomach cancer that has spread to nearby tissues but not to other organs. You would get a short course of radiation, followed by a combination of targeted therapy (Disitamab Vedotin), chemotherapy (S-1), and immunotherapy (Sintilimab) before surgery to shrink the tumor and improve outcomes.
This trial tests two drugs, disitamab vedotin and trastuzumab, for people with HER2-positive stomach or gastroesophageal junction cancer that has spread or come back after at least one prior treatment. The goal is to see if this combination can help shrink tumors.
Hear when a new Gastric Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.